The anticancer drugs paclitaxel and methotrexate are associated with sometimes severe and even lethal toxicity in patients. Paclitaxel has a narrow therapeutic window, and often leads to hypersensitivity, neutropenia and neurotoxicity. Methotrexate toxicity (mucositis, renal and hepatic toxicity) has been correlated with plasma levels of the drug. Using Slco1a/1b -/-mice, we
INTRODUCTION
Organic anion transporting polypeptides (OATPs/Oatps; gene name: SLCO/Slco) form a superfamily of transmembrane uptake transporters. Each OATP subfamily contains several human and mouse members, which share at least 60% homology in their amino acid sequences.
For most of the human OATPs of the OATP1A and OATP1B subfamilies there are no straightforward mouse orthologs, for example the OATP1A subfamily contains only one human protein, OATP1A2, but at least four mouse members have been described (Oatp1a1, -1a4, -1a5, and -1a6). On the other hand, the OATP1B family is represented by two human members, OATP1B1 and OATP1B3, and only one mouse protein, Oatp1b2. Human and mouse OATP1A/1B transporters are mainly expressed in liver, kidney and small intestine and are believed to have a profound impact on the absorption, distribution and elimination of many (often anionic or polar) drugs, including HMG-CoA-reductase inhibitors (statins), cardiac glycosides, antibiotics (rifampicin) and anticancer drugs (methotrexate, SN-38) (1-3).
The importance of OATP drug uptake transporters in the pharmacokinetics of drugs has become more evident with the discovery of genetic variants that influence their function. To date, a range of SNPs have been identified in the SLCO1B1, SLCO1B3 and SLCO1A2 genes, some of which occur frequently in several populations and are responsible for reduced transport capacities (3) (4) (5) . For example, SLCO1B1*15 [A388G and T512C] (haplotype frequency is 16, 24 and 12% in Europe, America and East Asia, respectively (5)) showed decreased transport properties for pravastatin, valsartan and SN-38, correlating with increased plasma levels of the drugs and, in case of SN-38, even life-threatening toxicities in patients (3;6). Additionally, Treviño et al.
recently showed in a genome-wide association study that two intronic SNPs in SLCO1B1, which were in linkage disequilibrium with each other and with the non-synonymous SNP T512C, were associated with increased clearance and increased gastrointestinal toxicity of methotrexate (MTX) (7) . And although one study in a European Caucasian population failed to demonstrate a link between genetic variants in SLCO1B3 and disposition of paclitaxel (PTX) (8) , another study These clinical studies clearly demonstrate that polymorphisms in SLCO1A/1B genes can contribute significantly to interindividual variation in disposition, toxicity and therapeutic response for a wide range of drugs. It is therefore important to understand the relative roles of OATP1A/1B transporters in drug pharmacokinetics in vivo, especially for anticancer drugs since these drugs often have narrow therapeutic windows. Our group recently generated and characterized a novel Oatp1a/1b transporter knock-out mouse model (Slco1a/1b -/-mice) (10) .
Since the various Oatp1a and -1b transporters of both mouse and human display a large overlap in tissue distribution and substrate specificity, we generated a mouse model lacking all Oatp1a and1b transporters. Using these mice we could show a pronounced role of Oatp1a/1b transporters in the physiological processes of bilirubin and bile salt distribution and disposition. Furthermore, the pharmacokinetics of some polar drugs (MTX and fexofenadine) was extensively affected by absence of these Oatp1a/1b transporters. The availability of the Oatp1a/1b transporter knock-out mouse now allows us to directly address a number of questions with respect to the in vivo roles of Oatp1a/1bs, which was not previously possible.
PTX is widely used in the treatment of breast and ovarian cancer, non-small cell lung cancer and Kaposi's sarcoma (11) . In contrast to MTX and fexofenadine, PTX is a very hydrophobic drug which is thought to easily pass cell membranes by passive diffusion. It is therefore assumed that drug uptake transporters, like Oatp1a/1b transporters, do not play an important role in the pharmacokinetics of PTX. Surprisingly, however, PTX was recently identified as a substrate of OATP1B3 in vitro (8;12) , although transport activity was low, and it was uncertain whether this would have significant impact in vivo.
The aim of this study was to elucidate the possible role of Oatp1a/1b transporters in PTX disposition in vivo by using Oatp1a/1b cluster knockout mice. We previously showed the value of knockout mice in studying the role of ABCB1 (P-glycoprotein, P-gp) and/or ABCC2 (Multidrug Heparinized blood samples were centrifuged at 5000 rpm for 5 min at 4°C and plasma was collected and stored at -20°C until analysis.
Plasma and tissue pharmacokinetic experiments

Drug analysis
Amounts of PTX in plasma and organs (homogenized in ice-cold 4% (w/v) BSA using a Polytron homogenizer) were determined using liquid-liquid and solid-phase extraction followed by reversed phase HPLC with UV detection, as described before (15) . Amounts of MTX and its hydroxylated metabolite 7OH-MTX in plasma and organs (homogenized in 4% ice-cold BSA)
were determined by HPLC analysis as described (16) .
Statistical analysis
Statistical evaluation was performed using the two-sided unpaired Student's t-test to assess the statistical significance of difference between two sets of data. Differences were considered to be statistically significant when P < 0.05.
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RESULTS
Role of Oatp1a/1b proteins in PTX pharmacokinetics in vivo
To determine the role of Oatp1a/1b transporters in the disposition of PTX in vivo, wild-type and Slco1a/1b -/-mice were dosed with PTX (10 mg/kg i.v.) and drug levels were measured at several time points after administration. The plasma area under the curve (AUC) was 2.2-fold increased in Slco1a/1b -/-mice compared with wild-type mice (1127 ± 47 min·μg/ml versus 503 ± 29 min·μg/ml, respectively; P < 0.001; Figure 1A ). Concomitantly, in spite of the higher plasma concentrations, PTX concentrations in the liver were markedly (2-fold) lower in mice lacking Oatp1a/1b transporters (liver AUC was 5258 ± 209 versus 10445 ± 479 min·μg/g for Slco1a/1b
and wild-type mice, respectively; P < 0.001; Figure 1B ), illustrating the impact of hepatic Oatp1a/1b transporters on PTX pharmacokinetics. From 7.5 min (second time point) after dosing onwards, liver-to-plasma ratios were markedly higher in wild-type compared with Slco1a/1b -/-mice, and they tended to further increase with time (and thus lower plasma PTX concentrations) ( Figure 1C ). Given the hydrophobic nature of PTX, we had anticipated that there would be a substantial passive diffusion component in its tissue distribution. Indeed, the rather constant liverto-plasma ratio over time in Slco1a/1b -/-mice suggests that liver uptake of PTX is predominantly dependent on passive diffusion in absence of Oatp1a/1b transporters. In contrast, the increasing liver-to-plasma ratio over time in the wild-type mice may suggest a relative decrease in passive diffusion, and an increase in Oatp1a/1b contribution to PTX liver distribution with decreasing PTX plasma levels.
Shortly after PTX administration (7.5-15 min) more than 40% of the drug had accumulated in the wild-type liver, illustrating the rapid and profound impact of this organ on i.v. PTX pharmacokinetics ( Figure 1B) . Interestingly, liver accumulation of PTX in wild-type mice still increased from 3.5 min onwards (3.5-7.5 min P = 0.06; 3.5-15 min P < 0.05) and only dropped after 15 minutes, whereas in the absence of Oatp1a/1b transporters PTX concentration in the liver only decreased over this time period. This effect was verified in an independent experiment (data Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research not shown). At the early time point of 3.5 minutes after administration, no significant differences in liver and plasma PTX were observed between wild-type and Slco1a/1b -/-mice ( Figure 1 ).
Together, these data suggest that at very high plasma concentrations (0-3.5 min after dosage; > ~20 μg/ml), the Oatp1a/1b-mediated liver uptake of PTX is saturated and hepatic PTX uptake is predominantly dependent on other uptake mechanisms, most likely passive diffusion, in both wild-type and Slco1a/1b -/-mice. Thereafter, Oatp1a/1b transporters start to exert a marked effect on PTX distribution to the liver, even when plasma concentrations are as low as 0.3 μg/ml ( Figure   1 ).
Dose-dependent role of Oatp1a/1b transporters in PTX pharmacokinetics
Because of the suggestion of the involvement of saturation processes, wild-type and Slco1a/1b -/-mice were dosed with 2, 10 or 50 mg/kg PTX to establish the role of Oatp1a/1b transporters in PTX disposition at different dose levels and plasma concentrations. Tissue and plasma levels of PTX were determined 30 minutes after administration, as at this time point, based on the data in Figure 1 , the early distribution phase was over and the impact of Oatp1a/1b on both plasma and liver concentrations was substantial. Plasma levels of PTX were clearly increased in mice lacking Oatp1a/1b transporters compared with wild-type mice at all dosage levels (2.1-, 1.9-and 1.7-fold increased upon 2, 10 and 50 mg/kg PTX dosage, respectively; Figure 2A ). Also the hepatic levels of PTX confirmed a high impact of Oatp1a/1b transporters on PTX distribution over a broad concentration range, since liver accumulation was significantly decreased in Slco1a/1b -/-mice compared with wild-types at all three dose levels (1.8-, 2.2-and 1.5-fold decreased upon 2, 10 and 50 mg/kg PTX dosage, respectively; Figure 2B ). Although the effect of Oatp1a/1b transporters on plasma and liver levels of PTX after 50 mg/kg dosage was still marked (1.7-and 1.5-fold, respectively), the fold difference between wild-type and Slco1a/1b -/-mice was significantly lower than after the dosage of 2 mg/kg PTX (P < 0.05 for both plasma and liver levels of PTX). This is compatible with a beginning of saturation of the Oatp1a/1b-mediated uptake of PTX into the liver at higher plasma concentrations (>20 ug/ml).
Higher dosages of PTX were not tolerated by the mice, precluding attempts to fully saturate the Oatp1a/1b uptake component. The white bars shown in Figure 2B correspond to the uptake of PTX into the liver in the absence of Oatp1a/1b transporters. Hypothetically, when PTX is fully dependent on Oatp1a/1b transporters for transporter-mediated uptake into the liver, these white bars represent the remaining passive diffusion-mediated liver uptake of PTX. The part of PTX uptake (% of dose) into the liver mediated by passive diffusion was rather constant at all three dosages, as would be expected for a non-saturable process. In fact, these results suggest that at 2 and 10 mg/kg dose ~50% of the PTX accumulation in the liver was mediated by active uptake through Oatp1a/1b and the other ~50% most likely by passive diffusion. At the highest dose (50 mg/kg), however, the Oatp1a/1b-mediated liver uptake of PTX (black bar minus white bar) is clearly decreased (to ~30% of total uptake), suggesting partial saturation of Oatp1a/1b transporters.
We also tested PTX levels in small intestine (including contents) 30 minutes after dosing.
These were slightly (albeit not significantly) increased in Slco1a/1b -/-mice dosed with 2 or 50 mg/kg PTX, but significantly increased in Slco1a/1b -/-mice after 10 mg/kg ( Figure 2C ). These results are in line with previous reports that have shown the importance of P-glycoprotein-and Mrp2-mediated direct intestinal excretion after i.v. administration of PTX (13;14) . This direct intestinal excretion of PTX is likely dependent on plasma levels of the drug (14) , and our results suggest that a presumably decreased biliary excretion of PTX in Slco1a/1b -/-mice (due to the decreased liver PTX levels) is more than off-set by an increase in direct intestinal excretion (owing to the increase in plasma PTX levels).
Dose-dependent role of Oatp1a/1b transporters in MTX pharmacokinetics
We have previously found that Oatp1a/1b deficiency has a pronounced effect on the pharmacokinetics of MTX at a dose of 10 mg/kg i.v., with a 4.8-fold increased plasma AUC, and
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Copyright © 2010 American Association for Cancer Research 25-fold decreased liver levels of MTX (10) . To investigate the effect of Oatp1a/1b transporters on plasma and tissue distribution after much higher doses of MTX, also aiming for a possible saturation effect, we administered 10, 50 and 500 mg/kg MTX i.v. to wild-type and Slco1a/1b -/-mice. Plasma, liver and small intestine (including contents) were isolated 15 minutes after administration (clearance of MTX is considerably faster than that of PTX) and MTX levels were determined. Plasma levels of MTX were markedly higher in Slco1a/1b -/-mice compared with wild-type mice at all three dose levels (5.8-, 5.7-and 3.4-fold increased upon 10, 50 and 500 mg/kg MTX, respectively; Figure 3A ). Liver levels of MTX, on the other hand, were far lower in mice lacking Oatp1a/1b transporters (23.2-, 18.4-and 30.2-fold decreased upon 10, 50 and 500 mg/kg MTX dosage, respectively; Figure 3B ). Small intestinal levels of MTX were also substantially decreased in Slco1a/1b -/-mice (10.0-, 18.9-and 12.9-fold decreased for 10, 50 and 500 mg/kg MTX, respectively; Figure 3C ), most likely reflecting the decreased liver concentrations, resulting in reduced biliary excretion (note that direct excretion of MTX across the intestinal wall is extremely low, even in wild-type mice (17;18) ).
Together, these data show a profound impact of Oatp1a/1b transporters on plasma levels and liver uptake over a wide range of MTX concentrations. Even at the highest practically attainable dose (500 mg/kg) the amount of MTX in the liver of Slco1a/1b -/-mice was only <1% of the dose, whereas in wild-type mice this was ~25% ( Figure 3B ). In contrast to the PTX data where we could show a beginning of saturation of Oatp1a/1b-mediated liver uptake of PTX at 50 mg/kg, even at 500 mg/kg MTX dosage no significant saturation of Oatp1a/1b transporters was noticed. to Oatp1a/1b. Due to the apparently very high capacity and K m of Oatp1a/1bs for MTX, these uptake transporters exert an immediate effect on MTX liver uptake and plasma levels, even at very high plasma concentrations. The beginning saturation of PTX liver uptake ( Fig. 2A, B) , and the contrasting absence of saturation of MTX liver uptake with higher drug dosages (Fig. 3A, B) further support this interpretation.
Importantly, our results indicate that the role of OATP1A/1B transporters in PTX pharmacokinetics might be clinically relevant, since the peak plasma concentration of PTX in patients after high-dose treatment (275 mg/m 2 ) can vary from ~2 to ~11 μg/ml (19) . This is well below the concentration where diffusion is the likely dominant factor for PTX liver uptake and plasma levels. Furthermore, neutropenia is related to plasma concentrations ≥ ~0.08 μg/ml (20;21). Therefore, OATP1A/1B transporters are most likely not saturated over the clinically relevant range of PTX plasma levels and they might thus markedly contribute to PTX kinetics and/or toxicity. Hence, reduced activity of OATP1A/1B transporters due to polymorphisms or drug-drug interactions might have severe consequences for patients treated with PTX.
The majority of human OATPs have also been detected in certain cancers. OATP1B3, for example, is found in gastric, colon, and pancreatic cancers (22) , in breast carcinomas (23) , and lung cancer (24) . OATP1A2 and OATP2B1 have also been detected in breast tumors (25) administration of 10 mg/kg MTX, the plasma concentrations were 1.9 ± 0.4 μg/ml in wild-type and 11.2 ± 3.1 μg/ml in Slco1a/1b -/-mice. All data are presented as means ± S.D. (n = 4-5; *, P < 0.05; **, P < 0.01; ***, P < 0.001 when compared with wild-type).
